Johnson & Johnson MedTech Launches VARIPULSE Platform for Atrial Fibrillation in Asia-Pacific
US major Johnson & Johnson MedTech announced the launch of its VARIPULSE Platform in the...
Johnson & Johnson
J&J Submits sNDA to FDA for Caplyta to Prevent Schizophrenia Relapse
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced the submission of a supplemental New...
FDA Removes REMS Requirements for BCMA- and CD19-Targeted CAR-T Therapies
The U.S. Food and Drug Administration (FDA) last week announced the removal of Risk Evaluation...
J&J’s Darzalex SC Recommended by CHMP for High-Risk Smoldering Multiple Myeloma
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...
Johnson & Johnson’s Imbruvica Secures CHMP Recommendation for Expanded MCL Use
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products...
Johnson & Johnson Submits sBLA to Expand Stelara Use for Pediatric Crohn’s Disease
US giant Johnson & Johnson (J&J, NYSE: JNJ) this week submitted a supplemental Biologics License...
Legend Biotech Plans to Disband China Sales Team Amid Carvykti Commercialization Challenges
Reports indicate that China-based Legend Biotech Corporation (NASDAQ: LEGN) plans to disband its China sales...
Johnson & Johnson Launches Tremfya IV in China for Inflammatory Bowel Diseases
US-based Johnson & Johnson (J&J; NYSE: JNJ) announced the commercial launch of Tremfya (guselkumab) intravenous...
JNJ Reveals Positive AMPLITUDE Phase III Results for Akeega in mHSPC at ASCO 2025
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced initial results from the Phase III...
Bio-Thera Solutions’ BAT2206 Biosimilar of Stelara Gains FDA Approval
Guangzhou-based Bio-Thera Solutions Ltd. (SHA: 688177) announced that it has received Biologic License Application (BLA)...
J&J’s Tremfya Approved for Ulcerative Colitis in China
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received marketing approval...
European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment
Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...
Johnson & Johnson’s Imaavy Gains FDA Approval for Generalized Myasthenia Gravis
US giant Johnson & Johnson (J&J, NYSE: JNJ) unveiled a market approval in the United...
Johnson & Johnson’s TAR-200 Shows Promising Results in Phase IIb SunRISe-1 Study for Bladder Cancer
US giant Johnson & Johnson (J&J; NYSE: JNJ) has released the first results from Cohort...
Johnson & Johnson’s Rybrevant Gains NMPA Approval for Expanded Lung Cancer Indication
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received another indication...
Johnson & Johnson’s Tremfya Approved by EC for Ulcerative Colitis Treatment
US giant Johnson & Johnson (J&J; NYSE: JNJ) announced that it has received regulatory approval...
Johnson & Johnson Reports Q1 2025 Revenue Growth, Led by Innovative Medicines and MedTech
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) reported Q1 2025 revenues of USD...
Johnson & Johnson Launches Rybrevant in China for EGFR Exon 20 Insertion Mutation Lung Cancer
US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ) has officially launched Rybrevant (amivantamab), an...
J&J’s Rybrevant SC Formulation Approved by EC for NSCLC Treatment
The European Commission (EC) has approved the subcutaneous (SC) formulation of Johnson & Johnson’s (J&J,...
J&J’s Darzalex SC Formulation Approved for Newly Diagnosed Multiple Myeloma
Johnson & Johnson (J&J, NYSE: JNJ) announced that it has received clearance from the European...